Most rare diseases have no natural history study, so drug developers can't design clinical trials and the FDA can't evaluate treatments

To design a clinical trial for a rare disease, you need to know what the disease actually does over time without treatment: how fast it progresses, what the measurable milestones of decline are, which biomarkers correlate with symptoms, and what the variability looks like across patients. This information comes from natural history studies -- systematic longitudinal observation of untreated patients. For the vast majority of the 10,000+ known rare diseases, no such study exists. There is little existing knowledge on the initial manifestations, major symptoms, day-to-day functional limitations, and progression patterns. Without this data, a drug developer cannot select appropriate endpoints, cannot power a trial correctly, and cannot construct an external control arm. The result is a Catch-22: you can't get a drug approved without clinical trial data, and you can't design a clinical trial without natural history data that nobody has collected. The FDA has explicitly recognized this gap as one of the primary bottlenecks in rare disease drug development. In response, the agency has funded natural history studies through its Orphan Products Grants Program and published guidance documents on how to conduct them. In 2024, the FDA established a Rare Disease Policy and Portfolio Council (RDPPC) and a Rare Disease Innovation Hub specifically to accelerate this work. But the scale of the problem dwarfs the response: there are thousands of conditions where the basic biology is understood (the gene is known, the mechanism is characterized, animal models exist) but there is no systematic human data on how the disease actually presents and progresses. Academic proof-of-concept studies sit in journals with no path to clinical translation. The structural barrier is that natural history studies are expensive, slow, and unglamorous. They require following patients for years, often across multiple countries (since any single center may only have a handful of patients), with no guarantee that a drug will ever be developed to treat the condition. No pharmaceutical company will fund a natural history study for a disease they're not sure they'll pursue commercially. Academic grants are competitive and short-term. Patient advocacy groups try to fill the gap but lack the epidemiological infrastructure to run rigorous longitudinal studies. The FDA's recent willingness to accept real-world data and external control arms is promising, but it requires the data to actually exist in a standardized, analyzable format -- which, as the registry fragmentation problem shows, it usually doesn't. Until someone systematically funds natural history data collection for the thousands of rare diseases that have none, the pipeline from lab discovery to patient treatment will remain blocked at the evidence generation stage.